Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapansutrile Plus Pembrolizumab in PD-1 Refractory Advanced Melanoma
NCT04971499Phase 2Active, not recruiting
- Start
- Sep 2022
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dapansutrile in melanoma (2 arms). Primary endpoints: Number of Adverse Events at 90 days and Objective Response Rate up to 2 years. Started Sep 2022; status: active, not recruiting.
02
Drugs
dapansutrile
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04971499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04971499.